Overview

A Study of AK0529 in Chinese Infants Hospitalized With RSV

Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, multicenter, phase III study to be conducted in infants hospitalized with RSV infection in China. The main objectives of this study are to investigate the efficacy and safety of AK0529 in Chinese infants.
Phase:
Phase 3
Details
Lead Sponsor:
Ark Biosciences Inc.
Collaborator:
Shanghai Ark Biopharmaceutical Co., Ltd.
Treatments:
Ziresovir